148 related articles for article (PubMed ID: 33832116)
1. How to prophylactically alleviate postembolization syndrome following transarterial chemoembolization?: Protocol of a double blinded, randomized, placebo-controlled trial.
Pan Y; Chang R; He Z; Hong M
Medicine (Baltimore); 2021 Apr; 100(14):e25360. PubMed ID: 33832116
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study.
Yang H; Seon J; Sung PS; Oh JS; Lee HL; Jang B; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
J Vasc Interv Radiol; 2017 Nov; 28(11):1503-1511.e2. PubMed ID: 28941589
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
[TBL] [Abstract][Full Text] [Related]
4. Jian Pi Li Qi Decoction Alleviated Postembolization Syndrome Following Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial.
Xu L; Wang S; Zhuang L; Lin J; Chen H; Zhu X; Bei W; Zhao Q; Wu H; Meng Z
Integr Cancer Ther; 2016 Sep; 15(3):349-57. PubMed ID: 26590124
[TBL] [Abstract][Full Text] [Related]
5. A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization.
Yinglu F; Changquan L; Xiaofeng Z; Bai L; Dezeng Z; Zhe C
J Altern Complement Med; 2009 Feb; 15(2):175-81. PubMed ID: 19216654
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma.
Simasingha N; Tanasoontrarat W; Claimon T; Sethasine S
World J Gastroenterol; 2023 Feb; 29(5):890-903. PubMed ID: 36816622
[TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Nagai K; Nakagawa T; Sugawara T; Hanaoka H; Kanai F; Yokosuka O
Hepatology; 2018 Feb; 67(2):575-585. PubMed ID: 28746788
[TBL] [Abstract][Full Text] [Related]
8. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
Sakamoto T; Saito Y; Kobayashi M; Yamada T; Takekuma Y; Nakai M; Ogawa K; Iseki K; Sugawara M
Support Care Cancer; 2020 Jul; 28(7):3251-3257. PubMed ID: 31732854
[TBL] [Abstract][Full Text] [Related]
9. [Chinese herbal medicine for side effects of transarterial chemoembolization in liver cancer patients: a systematic review and meta-analysis].
Li XQ; Ling CQ
Zhong Xi Yi Jie He Xue Bao; 2012 Dec; 10(12):1341-62. PubMed ID: 23257126
[TBL] [Abstract][Full Text] [Related]
10. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma.
Khalaf MH; Sundaram V; AbdelRazek Mohammed MA; Shah R; Khosla A; Jackson K; Desai M; Kothary N
Radiology; 2019 Jan; 290(1):254-261. PubMed ID: 30299233
[TBL] [Abstract][Full Text] [Related]
11. [Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].
Feng YL; Ling CQ; Zhu DZ; Yu CQ; Chen Z; Li B
Zhong Xi Yi Jie He Xue Bao; 2005 Mar; 3(2):99-102. PubMed ID: 15763053
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization.
Arslan M; Degirmencioglu S
Curr Med Imaging Rev; 2019; 15(4):380-385. PubMed ID: 31989907
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment.
Lima M; Dutra S; Gomes FV; Bilhim T; Coimbra É
Acta Med Port; 2018 Jan; 31(1):22-29. PubMed ID: 29573765
[TBL] [Abstract][Full Text] [Related]
14. Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
Wang SY; Zhu WH; Vargulick S; Lin SB; Meng ZQ
Asian Pac J Cancer Prev; 2013; 14(10):5995-6000. PubMed ID: 24289614
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
[TBL] [Abstract][Full Text] [Related]
16. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma.
Rose DM; Chapman WC; Brockenbrough AT; Wright JK; Rose AT; Meranze S; Mazer M; Blair T; Blanke CD; Debelak JP; Pinson CW
Am J Surg; 1999 May; 177(5):405-10. PubMed ID: 10365881
[TBL] [Abstract][Full Text] [Related]
17. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
18. Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population.
Jia S; Fu Y; Tao H
Pharm Biol; 2020 Dec; 58(1):771-784. PubMed ID: 32767901
[TBL] [Abstract][Full Text] [Related]
19. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
